INVA Q2 2023 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$81M-25.2% YoY

Gross Profit

$57M70.4% margin

Operating Income

$18M22.8% margin

Net Income

$1M1.6% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$38M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$563M

Stockholders' Equity

$555M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$81M	$108M	-25.2%
Gross Profit	$57M	$108M	-47.3%
Operating Income	$18M	$83M	-77.6%
Net Income	$1M	$939,000	+36.3%

Revenue Segments

Royalty

$62M77%

Product

$16M19%

License Revenue

$3M4%